Redwire Corporation Stock Price, News & Analysis

Redwire Corporation (NYSE: RDW) has been selected by NASA to facilitate a Space Microalgae biotechnology experiment on the International Space Station (ISS) during Axiom Mission 4 (Ax-4). The experiment, developed by Indian research organizations ISRO, ICGEB, and NIPGR, will study how microgravity affects three edible microalgae strains as potential sustainable food sources for long-duration space missions. Redwire will manage mission integration, scientific fulfillment, and operations. The mission represents significant international cooperation, featuring crew members from India, Poland, Hungary, and the US. Redwire, with three decades of spaceflight experience and nine ISS payloads, brings extensive expertise in space biotechnology, having achieved milestones like bio-printing the first human knee meniscus and heart tissue in space.

Redwire Corporation (NYSE: RDW) has amended its merger agreement to acquire Edge Autonomy for $925 million. The revised deal structure includes $160 million in cash (including a $100 million promissory note) and $765 million in Redwire stock at $15.07 per share. The promissory note carries interest rates of 15-18% with a 3% upfront fee. The company has secured $90 million in debt financing commitments from multiple banks. Additionally, Redwire has amended its existing credit facility, extending maturity to April 2027. The transaction has received board approval and support from major shareholders representing 69.2% of voting power. A stockholder meeting scheduled for June 9, 2025, will be adjourned to June 13, 2025, to allow shareholders additional time to review the amended agreement.

Redwire Corporation (NYSE: RDW) has achieved a significant milestone as its Mason technology suite passed NASA's Critical Design Review. Mason, developed under a $12.9 million NASA Tipping Point agreement, is designed to construct infrastructure on the Moon and Mars. The technology consists of three tools: BASE (grader), PACT (compaction), and M3LT (microwave sintering), which convert lunar/Martian regolith into concrete-like material for building landing pads, roads, and berms. This innovation addresses critical challenges of space exploration, including equipment damage from dust, health risks to astronauts, and orbital debris creation during launches. The platform-agnostic design allows integration with various space vehicles. Following the successful review, Redwire will proceed with prototype fabrication and functional testing while exploring demonstration mission opportunities.

Redwire Corporation (NYSE: RDW) has secured a contract from Aspera Biomedicines to conduct space-based research on a novel cancer treatment using Redwire's PIL-BOX technology. The research will focus on rebecsinib, an FDA-approved ADAR1 inhibitor entering first-in-human trials. Previous spaceflight experiments showed rebecsinib's potential as a cancer "kill switch" by inhibiting ADAR1 expression in triple-negative breast cancer models. The upcoming mission will analyze ADAR1p150's crystal structure with and without rebecsinib to enhance drug formulation development. The research leverages PIL-BOX, Redwire's premier pharmaceutical research platform that has completed 28 units to date, with the investigation scheduled for launch later this year.

Redwire Corporation (NYSE: RDW) has successfully delivered the onboard computer for the European Space Agency's (ESA) Comet Interceptor mission. The computer, developed by Redwire Space NV, will serve as the mission's "brain," monitoring and controlling spacecraft components and transmitting critical data to ground operators. The system is part of Redwire's third-generation Advanced Data and Power Management System (ADPMS-3).

The delivery follows comprehensive acceptance testing, including vibration, thermal vacuum, and electromagnetic compatibility tests. The mission, scheduled to launch in 2029, will be the first to visit a pristine comet from the outer Solar System. The same computer system is also supporting ESA's Hera planetary defense mission.

Redwire's European facility boasts over 40 years of spaceflight experience and continues to support various ESA programs, including Skimsat, the International Berthing and Docking Mechanism, and the Proba-3 mission.

Redwire Corporation (NYSE:RDW) has secured a contract from SpaceTech GmbH to provide critical avionics technology for ESA's Next Generation Gravity Mission (NGGM) satellites. The NGGM satellites will be part of the Mass Change and Geophysics International Constellation (MAGIC), a joint NASA-ESA Earth observation project combining four satellites to measure Earth's gravitational field fluctuations.

Through its subsidiary Redwire Space NV, the company will design and build the engineering qualification model of the spacecraft's Instrument Control Unit (ICU), which will manage the NGGM's primary scientific instrument. The mission aims to monitor water management applications, including droughts, floods, ice melts, and sea level rise. Redwire's European facility boasts over 40 years of spaceflight heritage and has successfully delivered technology for key ESA programs, including IXV and the Proba series.

Redwire Corporation (NYSE: RDW) reported its Q1 2025 financial results, showing mixed performance. Revenue decreased 30.1% to $61.4 million compared to $87.8 million in Q1 2024. The company reported a net loss of $2.9 million, an improvement from $8.1 million loss in Q1 2024. The Book-to-Bill ratio improved to 0.92, up from 0.40 year-over-year. Redwire maintained strong liquidity of $89.2 million, including $54.2 million in cash. The company announced significant developments, including the pending acquisition of Edge Autonomy and new contracts from Thales Alenia Space and NASA. For 2025, Redwire forecasts combined revenues of $535-605 million and Adjusted EBITDA of $70-105 million, assuming the Edge Autonomy transaction completion.

Redwire Corporation (NYSE:RDW) announced that its Chief Scientist, Dr. Kenneth Savin, has been named to TIME100 Health's 2025 list of most influential people in global health. Dr. Savin was recognized for his pioneering work in space biotech research, including groundbreaking achievements like bioprinting the first human knee meniscus and cardiac tissue on the International Space Station (ISS). His work at Redwire includes coordinating protein crystallization investigations with pharmaceutical companies like Eli Lilly and Bristol Myers Squibb using Redwire's PIL-BOX lab, focusing on drug development for various conditions including antiviral, antifungal, and antiseizure applications.

Prior to Redwire, Dr. Savin spent 20 years at Eli Lilly leading R&D teams and conducting ISS investigations, followed by a role as Senior Director at the ISS National Lab where he developed the In Space Production and Applications program.

Redwire Corporation (NYSE: RDW) has scheduled its first quarter 2025 financial results announcement for May 12, 2025, before market open. The company will host a conference call at 9 a.m. EDT the same day to discuss the Q1 2025 results.

The earnings call will be accessible via phone (toll-free: 877-485-3108 or toll: 201-689-8264) using conference ID 13753501. A live webcast with slides will be available through the company's investor relations website. For those unable to attend live, a replay will be available for two weeks following the event.